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Introduction {#sec1.1}
------------

Disturbances in smell and taste have emerged as the predominant neurological symptom of the coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2. Perhaps as many as 80% or more of patients infected with SARS-CoV-2 report anosmia, hyposmia, ageusia, dysgeusia, or changes in chemesthesis (the ability to sense chemical irritants) ([@bib59]; [@bib86]; [@bib93]; [@bib121]; [@bib153]; [@bib185]). Self-reported changes in chemical perception can predict whether a subject will test positive for SARS-CoV-2 ([@bib15]; [@bib54]; [@bib64]; [@bib111]; [@bib172]); one recent observational study that included more than two million participants revealed that the loss of smell and taste is more predictive than all other symptoms, including fatigue, fever, or cough ([@bib107]). Most of these studies have lacked objective chemosensory assessment, raising the possibility that chemosensory disturbances are even more prevalent than currently appreciated; indeed, smell testing reveals increased odor detection thresholds in a subset of COVID-19 patients who subjectively report a normal sense of smell ([@bib76]; [@bib82]; [@bib111]; [@bib132]). These findings have prompted researchers to develop accessible smell tests (in which individuals rate the quality and intensity of scents originating from, e.g., scratch-and-sniff cards or common kitchen items) for potential use as screening tools for COVID-19 ([@bib82]; [@bib133]).

The close relationship between COVID-19 and changes in chemical sensation raises questions about how SARS-CoV-2 might alter the cells and circuits charged with detecting stimuli and creating perception. Identifying these pathophysiological mechanisms has important implications for the development of possible treatments, as well as for the design of clinical chemosensory assessments to detect SARS-CoV-2 infection. Further, given that the COVID-19 syndrome is associated with neurological symptoms (including dizziness, headache, and altered consciousness) and stroke, characterizing these mechanisms may shed light on how SARS-CoV-2 disrupts neural systems more broadly ([@bib41]; [@bib69]; [@bib104]). Here we largely focus on interactions between SARS-CoV-2 and the olfactory system, which have been explored in some detail as the pandemic has progressed; as recent data suggest that SARS-CoV-2 may independently target taste and chemesthesis ([@bib121]), we also briefly speculate on possible pathophysiological mechanisms in those systems.

More Than the Common Cold {#sec1.2}
-------------------------

SARS-CoV-2 belongs to the coronavirus family, which includes the pandemic MERS-CoV and SARS-CoV and the lesser known but more common endemic coronaviruses HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63. The endemic coronaviruses can infect the upper airway and frequently cause the common cold, which in turn is associated with both acute and chronic changes in smell and taste ([@bib38]; [@bib103]; [@bib122]; [@bib138]; [@bib157]; [@bib181]). The main proposed mechanisms for acute viral-mediated changes in smell include conductive deficits caused by loss of patency due to swelling of the mucosa and increased mucus production, changes in mucus composition, and secondary changes in olfactory signaling caused by local release of inflammatory intermediates like cytokines ([@bib2]; [@bib27]; [@bib39]; [@bib142]; [@bib161]; [@bib170]; [@bib192]). While cold-causing viruses likely act through multiple mechanisms to influence smell, recovery from virus-associated olfactory deficits tend to resolve with a time course similar to that of other cold-related symptoms like nasal congestion ([@bib78], [@bib79]; [@bib193]).

In a subset of patients, viral infections lead to long-lasting (i.e., months) post-viral anosmia, which is thought to result from direct damage to the olfactory sensory neurons (OSNs) responsible for odor detection in the olfactory epithelium (OE) ([@bib24]; [@bib44]; [@bib178]; [@bib179]). Partial or full recovery of olfactory function in these patients is likely due to the recruitment of stem cells in the olfactory epithelium, which can replace damaged OSNs over long timescales. The recovery process is often accompanied by parosmias---distortions of smell perception---associated with wiring errors between newborn OSNs and their post-synaptic targets in the olfactory bulb (OB) ([Figure 1](#fig1){ref-type="fig"} ; [@bib97]; [@bib135]). Some cases of post-viral anosmia have been hypothesized to be the consequence of viral damage to central nervous system structures; in these cases, coronaviruses and other viruses are thought to gain access to the OB either directly via OSN axons or indirectly by passing through perforations in the cribriform plate ([Figure 1](#fig1){ref-type="fig"}; [@bib10]; [@bib143]; [@bib166]).Figure 1Chemosensory Anatomy Defines the Potential Attack Surface for SARS-CoV-2Chemosensation occurs in sensory epithelia in the nose and mouth. Multiple cranial nerves relay the senses of smell, taste, and chemesthesis to the brain. Airborne odors are detected by olfactory sensory neurons that reside in the olfactory epithelium; their axons pierce the bony cribriform plate to enter the olfactory bulb in the brain. Taste buds on the tongue are innervated by sensory afferents from the facial nerve (VII) and glossopharyngeal nerve (IX). The vagus nerve (X) also innervates taste buds residing in the pharynx. The detection of pungent chemicals, also known as chemesthesis, is mediated by both oral and nasal afferents of the trigeminal nerve (V). Although deficits in smell are most commonly reported in COVID-19, all three chemosensory modalities have been reported to be affected.

However, the natural history of COVID-19-associated anosmia argues that SARS-CoV-2 attacks the olfactory system through mechanisms distinct from those used by the more benign endemic coronaviruses. Many patients report anosmia as their first symptom, or in the absence of rhinorrhea or nasal congestion, suggesting that if inflammation is a key component of pathogenesis, it is local rather than generalized ([@bib59]; [@bib86]; [@bib94]; [@bib121]; [@bib153]; [@bib165]); indeed, the sensitivity of anosmia as a predictor of COVID-19 increases in patients without other nasal symptoms ([@bib64]; [@bib149]). Consistent with this observation, imaging studies of the olfactory system in COVID-19 patients are either normal or reveal focal inflammation ([@bib48]; [@bib58]). In addition, resolution of anosmia seems more rapid than observed in post-viral olfactory loss, in many cases occurring in weeks (rather than months) after initial symptoms develop ([@bib75]; [@bib86]; [@bib93]; [@bib185]). Finally, the limited data currently available suggest that parosmias are infrequent during or after COVID-19 recovery (although this may change as we learn more) ([@bib93]; [@bib121]).

Inferring Disease Mechanisms from Patterns of Gene Expression {#sec1.3}
-------------------------------------------------------------

Coronaviruses are so named because of the halo of spike (S) proteins that decorate their surface ([@bib42]; [@bib124]). These S proteins interact with specific cellular receptors to bind host cells; binding is followed by protease-mediated S protein cleavage, which exposes fusion-promoting domains that enable viral entry. SARS-CoV-2 infects cells through interactions between its S protein and the Angiotensin I Converting Enzyme 2 (ACE2) receptor on target cells; ACE2 plays a crucial modulatory role in the renin-angiotensin system, which regulates blood pressure and salt water balance ([@bib5]; [@bib146]; [@bib173]; [@bib195]). Infection requires S protein cleavage, likely by the host cell serine protease TMPRSS2, although other proteases may also be involved ([@bib73], [@bib74]; [@bib189]). With the exception of HCoV-NL63, the endemic coronaviruses do not use ACE2 as their primary cellular receptor ([@bib14]; [@bib197]), a molecular distinction that likely underlies key differences in pathophysiology. SARS-CoV also uses ACE2 as its main receptor, and in one case study SARS-CoV infection was associated with anosmia ([@bib81]), although (unlike COVID-19) chemosensory disturbances are not a hallmark of SARS. Differences between SARS-CoV and SARS-CoV-2 in terms of their impacts on chemosensory systems may relate to biophysical differences, as the receptor-binding domain of the SARS-CoV-2 spike protein binds ACE2 with higher affinity and with a different binding mode than that of SARS-CoV ([@bib98]; [@bib145]; [@bib173]). Species variation in the protein sequence of ACE2 significantly affects its affinity for the SARS-CoV-2 S protein, which in turn renders distinct model organisms differentially susceptible to infection ([@bib174]; [@bib194]).

Given data suggesting that ACE2 is necessary for SARS-CoV-2 to infect host cells, researchers have used a variety of approaches to discern the pattern of expression of ACE2 and other viral entry proteins across the tissue landscape, with the goal of inferring possible target cells and disease mechanisms. For example, two studies have reported that cells in the nasal respiratory epithelium (RE) have higher expression of SARS-CoV-2 entry genes than cells in the RE that line the trachea or lungs ([@bib77]; [@bib155]). Consistent with this finding, recent work in macaques, ferrets, and cats identifies the nasal epithelium as a major source of viral RNA after SARS-CoV-2 infection ([@bib113]; [@bib147]). These data suggest that the nasal epithelium may act as a major reservoir for the virus ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} ).Figure 2ACE2-Positive Cells in the Nasal Respiratory Epithelium, Olfactory Epithelium, and the Olfactory BulbSchematic of a sagittal view of the human head, in which respiratory and olfactory epithelium as well as the olfactory bulb in the brain are colored (left). For each tissue, a schematic of the anatomy and known major cell types are shown (middle). The nose contains both respiratory and olfactory epithelia. The olfactory epithelium is restricted to medial portion of the superior turbinate and the superior portion of the nasal septum, whereas the respiratory epithelium is continuous with the upper airway ([@bib36]). Olfactory sensory neurons within the olfactory epithelium are responsible for detecting odors, and in mice and humans they are continuously regenerated from globose progenitors throughout life ([@bib45]; [@bib144]). The olfactory epithelium also contains other support and non-neuronal cell types, as well as reserve horizontal basal stem cells that respond to injury and can reconstitute olfactory epithelial cell types ([@bib32]). In the respiratory epithelium, basal progenitor cells generate all epithelial cell types, including ciliated and secretory cells. In the olfactory bulb in the brain (tan), the axons from olfactory sensory neurons coalesce into glomeruli, and mitral/tufted cells innervate these glomeruli and send olfactory projections to downstream olfactory areas. ACE2-positive cell types are indicated in gray (right). Four recent reports have all concluded that ACE2 is not expressed in olfactory sensory neurons ([@bib20]; [@bib29]; [@bib53]; [@bib196]). Pericyte ACE2 expression in the olfactory bulb is inferred from the mouse data; there are currently no available human olfactory bulb sequencing datasets. Figure modified from [@bib20].

Although much of the human nose is lined with RE, sensory detection occurs in the olfactory epithelium, which houses OSNs and is located in the superior-most regions of the nasal epithelium ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). The OE is a complex chemosensory tissue composed of multiple cell types, including immature and mature OSNs, non-neuronal cell types such as the sustentacular, Bowman's gland, and microvillar cells, and stem cells including globose and horizontal basal cells. Sustentacular cells are particularly intimately associated with OSNs, and they "enwrap" the sensory dendritic cilia that project into the airspace and enable odor detection ([@bib100]). Four recently published studies---using species ranging from mouse to human---have explored the cell types in the OE that express ACE2 and other viral entry genes ([@bib20]; [@bib29]; [@bib53]; [@bib196]); all four conclude that OSNs do not express ACE2 ([Figure 2](#fig2){ref-type="fig"}). Instead, co-expression of ACE2 and TMPRSS2 was observed in key support cells (including sustentacular, Bowman's gland, and microvillar cells) and stem cells that repopulate the epithelium after damage. Although ACE2 mRNA was identified using single-cell RNA sequencing (scSeq) techniques in only a small subset of these cells, both [@bib20] and [@bib53] have demonstrated high level expression of ACE2 protein in a large population of sustentacular cells concentrated in the dorso-medial aspect of the mouse OE, which corresponds to the dorsal "zone" traditionally identified via molecular markers ([@bib63]; [@bib110]). Consistent with this observation, mouse and human sustentacular cells identified as ACE2 positive by scSeq largely derive from the dorsal zone ([@bib20]).

The co-expression of ACE2 and TMPRSS2 suggests that OE support cells may be the initial targets of SARS-CoV-2 infection. These inference-based conclusions are increasingly being pressure-tested by experiments in which model organisms are directly subject to SARS-CoV-2 infection. One recent paper in the golden hamster reports that SARS-CoV-2 infects sustentacular cells but not OSNs ([@bib21]). Intriguingly, this phenotype is accompanied by damage to the OSN ciliary layer and an increase in the number of microglia present in the OE, both of which are partially reverted to normal at 14 days after infection. A similar study in the hamster identified a large number of cells in the OE that were infected by SARS-CoV-2, although OE cell types were not definitively identified; inspection of the photomicrographs in that paper reveals that most SARS-CoV-2-positive cells traverse the thickness of the OE, suggesting that sustentacular cells are primary targets for infection ([@bib150]). Human OE samples obtained from COVID-19 patients have similarly been queried for infection by SARS-CoV-2, which has revealed coronaviral antigens present in OE cells; infected cell types were not unambiguously identified, but their shape and position is consistent with the virus targeting sustentacular cells rather than OSNs ([@bib23]; [@bib106]).

What mechanisms might link infection of support cells to the acute changes in smell reported in COVID-19 ([Figure 3](#fig3){ref-type="fig"} )? Localized inflammation in the epithelium might block the olfactory clefts, a pair of narrow passages located in the superior regions of the nasal epithelium through which air must flow to reach the OE, which comprises only 5% of the total nasal epithelium in humans ([@bib17]; [@bib161]). Consistent with this possibility, a recent CT study of a COVID-19 patient who presented with anosmia revealed blocked olfactory clefts ([@bib48]). Alternatively, infection of support cells and the attendant inflammation may cause local increases in inflammatory intermediates such as cytokines, which have been shown to influence OSN function in a non-cell-autonomous manner ([@bib27]). Indeed, a recent study demonstrates elevated levels of inflammatory cytokines in the OE of infected patients ([@bib160]). Inflammatory intermediates have been suggested to indirectly lower the expression of odorant receptor (OR) genes by OSNs, which could cause significant changes in odor perception; this work also shows that OR expression levels return to normal after cessation of the inflammatory insult ([@bib133]).Figure 3Possible Mechanisms of Chemosensory Disturbances(A) COVID-19 patients have reported olfactory loss in the absence of features common to upper respiratory infections like widespread nasal inflammation or obstruction. Such symptoms are consistent with recent CT imaging suggesting that SARS-CoV-2 infection may cause inflammation that is localized to the olfactory clefts ([@bib48]).(B) Sustentacular cells, Bowman's gland cells, and microvillar cells in the olfactory epithelium express both ACE2 and TMPRSS2 and may be directly infected by SARS-CoV-2. Support cell infection may cause changes in the olfactory mucus or ion imbalances that can inhibit olfactory signaling; such changes may be rapidly reversible. The loss of these support cells in animal models can also result in the death of olfactory sensory neurons.(C) Inflammatory cytokines may also directly or indirectly inhibit olfactory sensory neuron function.(D) Although current data suggest that sustentacular and other support cells are the primary targets of SARS-CoV-2, a remaining possibility is that SARS-CoV-2 directly infects OSNs.(E) Immunostaining for ACE2 protein in the mouse olfactory bulb suggests that ACE2 expression is restricted to vascular pericytes ([@bib20]), which may directly (via perfusion changes) or indirectly (via inflammation) affect chemosensory perception in the brain.(F) Taste and chemesthetic disturbances may result from the direct infection of cells in the tongue, the secondary consequences of obstruction due to inflammation, or damage following the release of inflammatory cytokines.

Finally, SARS-CoV-2 infection of support cells might alter the OE microenvironment in a manner deleterious to function. Bowman's glands, for example, secrete mucus, which is essential to normal odor detection ([@bib40]; [@bib88]; [@bib151]). Sustentacular and microvillar cells remain somewhat mysterious, but seem to structurally support sensory neurons, phagocytose and/or detoxify potentially damaging agents, generate inflammatory cytokines, manage energetics through delivery of glucose to OSNs, and maintain local salt and water balance ([@bib12]; [@bib96]; [@bib118]; [@bib156]; [@bib163]; [@bib171]). Damage to support cells thus has the potential to change ion gradients and fuel availability, which in turn could acutely influence OSN firing rates. Furthermore, the important role of sustentacular cells in anatomically supporting OSN sensory cilia (which are surrounded by sustentacular cell processes) is highlighted by the observation that infection of sustentacular cells by SARS-CoV-2 in the golden hamster is linked to the denuding of OSN cilia, even in the absence of OSN infection ([@bib21]).

At least a subset of patients with COVID-19 appear to have longer-lasting anosmia, which may reflect more widespread damage to OSNs and the OE (as is seen in typical post-viral syndromes) ([@bib83]; [@bib94]; [@bib179]). Such damage could be a consequence of high levels of local inflammation, or a secondary consequence of the death of support cells, which in mouse models can lead to cascading changes in the structure and function of the OE ([@bib16]; [@bib27]; [@bib70]). Of note, the horizontal basal cells that are normally quiescent but play a particularly important role in regenerating damaged OE also express ACE2 ([@bib20]; [@bib144]); infection of these cells may therefore slow functional recovery over long time scales.

Is SARS-CoV-2 "Neuroinvasive"? Lessons from the Olfactory Bulb {#sec1.4}
--------------------------------------------------------------

Recent MRI studies have revealed transient changes in the OB that accompany COVID-related anosmia, consistent with some degree of central involvement in at least a subset of patients ([@bib92]; [@bib127]). Certain coronaviruses can pass from the OE through the cribriform plate to infect the OB ([@bib43]; [@bib46]). It remains unclear whether SARS-CoV-2 (given that it likely does not directly infect OSNs, and thus cannot pass directly through the olfactory nerve; see [Figure 1](#fig1){ref-type="fig"}) has this capacity; nevertheless, this possibility raises the question of whether SARS-CoV-2 can directly target neurons, glia, or other cell types in the OB. To date there are no scSeq datasets for the human olfactory bulb, and thus the distribution of ACE2 and other SARS-CoV-2-specific cell entry genes remains to be determined. However, scSeq and immunostaining of the mouse OB has revealed---as in the nose---that bulb neurons do not express detectable levels of ACE2 ([Figure 2](#fig2){ref-type="fig"}; [@bib20]). Consistent with this finding, targeted deep sequencing of dopaminergic juxtaglomerular cells, which receive direct inputs from nose OSNs, failed to reveal Ace2 mRNA ([@bib20]). Furthermore, OB cell targeting was not observed in studies of hamsters infected with SARS-CoV-2 ([@bib21]).

In contrast, vascular pericytes in the OB expressed high levels of ACE2 protein ([@bib20]), consistent with the reported expression of Ace2 in perivascular cells in the brain and throughout the body ([@bib28]; [@bib68]). Pericytes are critical for maintaining the blood-brain barrier, for defining local blood pressure, and for mediating neuroimmune responses ([@bib4]); infection of these cells thus has the potential to alter perfusion or recruit inflammation, both of which can indirectly influence the function of neural circuits. Thus, while vascular effects and inflammation could influence central brain structures involved in odor perception, current data suggest that it is unlikely that SARS-CoV-2 directly infects OB neurons responsible for processing odor information from the nose and conveying it to the cortex.

Consistent with observations in the OB, there is an increasing amount of data suggesting that ACE2 is not appreciably expressed in neurons in the brain at either the RNA or protein level. Meta-analysis of ten separate mouse deep-sequencing datasets drawn from across the central and peripheral nervous system did not reveal significant expression of either ACE2 or TMPRSS2 in any neural cell type ([@bib20]); scSeq analysis of human prefrontal cortex and hippocampus failed to identify any ACE2-expressing cells ([@bib30]); and multiple immunostaining studies have demonstrated ACE2 expression in brain vasculature but not in neurons or glia ([@bib20]; [@bib66]; [@bib87]). These expression-based studies are now being complemented by data from a variety of animal models that can be infected with SARS-CoV-2. Infection of macaques, cats, and ferrets with SARS-CoV-2 (which in the monkey and cat resulted in pulmonary infection) did not reveal any virus present in the brain ([@bib113]; [@bib147]). In addition, recent human autopsy studies reveal that the brain contains the least amount of SARS-CoV-2 of any sampled tissue in the body ([@bib130]).

In contrast to these observations, several reports have suggested that SARS-CoV-2 may be "neuroinvasive," which we take here to mean the direct infection of neurons or glia in the central nervous system ([@bib6]; [@bib99]; [@bib106]; [@bib112]; [@bib182]). Arguments supporting this position often refer to data demonstrating that coronaviruses can hop from the nose to the bulb in experimental mouse models ([@bib43]; [@bib46]; [@bib125]; [@bib166]); however, without exception, the coronaviruses that have this property either do not use ACE2 as a receptor, were explicitly selected during passage for their neurotropic potential, or both ([@bib22]; [@bib35]). Many lines of evidence for neuroinvasiveness are drawn from prior work on SARS-CoV and its ability to infect ACE2-expressing cells. For example, it has been observed that nasal instillation of SARS-CoV in mouse models expressing human ACE2 (which has much higher affinity for the CoV and SARS-CoV-2 spike protein than does mouse ACE2) can result in widespread infection of brain tissues ([@bib115]; [@bib162]; [@bib186]); however, these models transgenically express human ACE2 in many cells in which it is normally absent, making it an inappropriate tool to probe viral tropism. Although there is a case report describing detection of SARS-CoV RNA in the CSF of a patient, as this RNA could have originated from many cell types (including vascular cells), it does not clearly demonstrate the neuroinvasive potential of either SARS-CoV or SARS-CoV-2 ([@bib80]). Furthermore, two studies have failed to identify SARS-CoV-2 RNA in the CSF of patients ([@bib49]; [@bib140]). Notably, a recent experiment assessed the consequences of SARS-CoV-2 exposure in mice in which human ACE2 is transgenically expressed under control of the mouse ACE2 promoter (which should largely, although not perfectly, recapitulate endogenous patterns of ACE2 expression); while nasal infection and subsequent spread was sufficient to ultimately kill these mice, post-mortem analysis failed to reveal SARS-CoV-2 in the brain ([@bib7]).

However, other lines of evidence more directly support the possibility that SARS-CoV-2 can directly infect neurons or glia. In one patient autopsy sample, SARS-CoV was identified via antigen staining to be distributed across the brain parenchyma ([@bib183]). Two papers have reported Ace2 staining in astrocytes in the rat cerebellum and brainstem ([@bib57]; [@bib61]), a paper from the Human Cell Atlas has reported ACE2 expression in oligodendrocytes ([@bib114]), and a meta-analysis of a single scSeq dataset revealed low-level expression of ACE2 in human middle temporal gyrus and posterior cingulate cortex (although that same dataset included data for only a handful of vascular cells, making it difficult to assess relative expression levels) ([@bib30]). Two recent papers have observed anti-ACE2 staining in the mouse olfactory bulb, the first in a subset of mitral cells ([@bib19]), the second in all mitral cells ([@bib164]); the latter paper also reports the presence of ACE2 protein in all OSN nuclei (but not OSN cilia, raising the possibility of non-specific staining). Cortical neurons in human brain organoids (which express ACE2) can be infected by SARS-CoV-2 ([@bib60]). Perhaps most convincingly, nasal instillation of SARS-CoV-2 in a mouse with the human ACE2 gene knocked into the mouse Ace2 locus caused infection of brain neurons, although the number, distribution, and identity of these cells was not characterized ([@bib154]).

We are only now beginning to understand SARS-CoV-2 pathogenesis and so it is important to recognize key caveats in interpreting data suggesting SARS-CoV-2 does or does not infect neurons and glia directly. Conclusions drawn based upon the presence or absence of ACE2 message or protein depend upon the specific methods being used: for example, scSeq techniques have low sensitivity but an identifiable noise floor, whereas immunohistochemistry depends upon the vagaries of each anti-ACE2 antibody. Similarly, conclusions based upon SARS-CoV-2 infection of model organisms (transgenic or otherwise) depend upon the expression pattern and S protein affinity of the ACE2 protein in each model, as well as a number of other species-specific factors relating to viral tropism and immune responses. It is clear that there are significant inconsistencies among the datasets that require reconciliation; definitively addressing the question of whether SARS-CoV-2 can infect human neurons (in the bulb or elsewhere) will ultimately require detailed analysis of autopsy tissue. It is also important to note that SARS-CoV-2 in principle has access to the brain through routes independent of the nasal epithelium, including via vasculature and nerves innervating infected tissues; these modes of infection have been observed for other viruses ([@bib37]; [@bib90]).

In light of this controversy, it is worth noting that many of the observed neurological consequences of COVID-19 (like altered consciousness and stroke) can in principle be explained by a primary vasculopathy and hypercoagulability ([@bib31]; [@bib69]; [@bib191]) or by a secondary deficit in brain perfusion caused by elevated cytokines ([@bib128]). In contrast, clinical signs of encephalitis (i.e., infection of neurons), such as increased risk of seizures and inflammatory CSF, have not been commonly observed ([@bib102]). This perspective is consistent with recent MRI findings in COVID-19 patients ([@bib18]; [@bib34]), and two separate autopsy series that failed to identify any signs of encephalitis ([@bib140]; [@bib152]). At this point, therefore, the balance of the clinical evidence points to SARS-CoV-2 influencing the brain indirectly through effects on vasculature, although this view may change as we learn more about viral pathogenesis and we gain access to more detailed clinical information.

SARS-CoV-2 Targets Taste and Chemesthesis {#sec1.5}
-----------------------------------------

Smell, taste, and chemesthesis are readily distinguishable but synergize to create the perception of the flavor in the mouth. A vast spectrum of volatile food odors is detected retronasally by OSNs, while the taste repertoire is restricted to non-volatile sour, salt, sweet, bitter, and umami stimuli that directly activate taste buds on the tongue. The spiciness of chili peppers and the cool of mint are neither odors nor tastes, but rather activate sensory neurons of chemesthesis that innervate oral epithelia. Most recent reports of smell loss in COVID-19 patients (see above) have generally considered smell and taste loss as unitary and excluded consideration of chemesthesis altogether. Importantly, recent data suggest that taste and chemesthesis may be disturbed independently of smell in COVID-19 patients ([@bib1]; [@bib93]; [@bib121]; [@bib165]). For example, [@bib121] showed that ∼60% of participants link taste loss (which could be attributed to flavor) to deficits in at least one specific taste quality (e.g., salty taste), suggesting that at least some participants distinguish changes in the taste component of flavor. However, the basic taste modalities were not predictably affected, with some taste qualities being differentially impacted across individuals. What mechanistic hypotheses can explain the specific impact of SARS-CoV-2 on taste function, and which cell populations may be targeted by the virus such that their loss would lead to distorted taste? Taste perception is supported by taste buds, which have a characteristic distribution on the tongue and which house taste receptor cells (TRCs) that are categorized into three morphological types ([Figure 4](#fig4){ref-type="fig"} ): type I for support, type II for sweet, bitter, or umami, and type III for sour) ([@bib25]). Like OSNs, individual TRCs are constantly being renewed by stem cells, and thus taste function and perception also depend on rapid and reliable production of the proper proportions of each of the different TRCs ([@bib9]).Figure 4Organization of the Tongue and Taste Buds(A) In the front of the tongue, taste buds are situated in fungiform papillae (FFP). FFP are distributed throughout the anterior lingual epithelium, which is covered by mechanosensory filiform papillae (flp). In the posterior tongue, large complex papillae (circumvallate \[CVP\] and foliate \[FolP\]) are epithelial invaginations that house hundreds of buds each; rodents have a single CVP, while humans possess 8--12 CVPs in an inverted V arrangement across the posterior tongue (not shown). Modified from [@bib8].(B) Each bud is a collection of ∼100 taste receptor cells (TRCs) categorized into three morphological types (I for support or glial-like, II for sweet, bitter, umami, and III for sour). All TRCs are continuously renewed from basal stem cells adjacent to taste buds ("Basal cells") ([@bib56]; [@bib101]; [@bib119]). Taste bud-fated daughters generated by basal cells exit the cell cycle and enter buds as postmitotic TRC precursors, which differentiate into each of the TRC types ([@bib108], [@bib109]). Basal cells also give rise to keratinocytes of the non-taste lingual epithelium including those surrounding taste buds. Individual TRCs have a brief lifespan ranging from 1 to 6 weeks ([@bib13]; [@bib65]; [@bib123]). Type III TRCs make conventional presynaptic contacts, while type II TRCs have specialized contacts with sensory afferents to transmit taste information to the CNS ([@bib52]; [@bib134]; [@bib137]; [@bib158]).(C) To date, RNA profiling of taste relevant cell populations has been obtained primarily from murine CVP, with two additional datasets for general anterior tongue epithelium in mice and human (see text). A summary of approximate ACE2 expression levels extracted from these studies is depicted here as discussed in the text. Of note, type I TRCs and precursor TRCs have yet to be profiled, and ACE2 is not detected in sensory neuron afferents.

Although formal analyses are only now emerging, a cursory mining of publicly available datasets of type II and III TRCs in mice reveals that ACE2 is expressed by sour-sensing type III TRCs, and to a lesser extent by bitter and sweet/umami-sensing type II TRCs ([@bib67]; [@bib95]; [@bib131]; [@bib148]; [@bib190]). While type II and type III TRCs express little to no TMPRSS2, Cathepsins (CTSB, CTSL) are abundant and may function as proteases to cleave SARS-CoV-2 spike protein at type II and III TRCs. Available datasets do not include transcriptional profiling for the type I TRCs, which---much like olfactory sustentacular cells---extend cellular processes that wrap type II and III TRCs ([@bib100]; [@bib187]). In addition, type I cells degrade ATP, which is used as a neurotransmitter by type II cells to convey taste information to the brain via the gustatory nerves ([@bib11]; [@bib52]; [@bib167]). If type I cells are indeed ACE2 positive and targeted by SARS-CoV-2, the loss of support cells could lead to taste bud collapse via cell death and/or reduced efficacy of taste signals to gustatory nerves ([Figure 3](#fig3){ref-type="fig"}). While human taste tissue has yet to be profiled, microarray data comparing macaque taste and non-taste lingual epithelia reveal low levels of ACE2, TMPRSS2, CTSL, and CTSB in both tissue compartments ([@bib71]), suggesting that the machinery necessary for SARS-CoV-2 infection of taste-relevant cells may be present in humans.

Adult taste stem cells in the posterior tongue (where they are most abundant) express the marker LGR5 and can give rise to all TRC lineages ([@bib188]). Despite a limited sample size, scSeq profiling revealed that murine LGR5-positive stem cells express ACE2 and TRMPSS2 and thus may be competent for infection by SARS-CoV-2 ([Figure 4](#fig4){ref-type="fig"}; [@bib131]). These data raise the possibility that taste dysfunction in COVID-19 patients may be caused or exacerbated by insufficient TRC renewal due to SARS-CoV-2 stem cell damage. In addition, it has been shown that experimentally induced systemic inflammation in mice can reduce taste stem cell output, which in turn leads to depopulated taste buds and perturbed taste function ([@bib33]; [@bib50]; [@bib85]; [@bib89]; [@bib175], [@bib176]). If SARS-CoV-2 directly infects the tongue, local inflammatory processes could therefore alter stem cell properties and ultimately influence taste perception ([Figure 3](#fig3){ref-type="fig"}). Consistent with this possibility, scSeq analysis in mice and humans suggests that ACE2 is highly expressed in subsets of tongue epithelial cells, as are other proteases linked to coronavirus entry, e.g., TMPRSS11D, TMPRSS4, and CTSB ([@bib126]; [@bib141]; [@bib168]; [@bib184]).

It is important to note that---unlike OSNs---TRCs are not neurons; thus, all of the cell types identified as ACE2 positive in the tongue to date are either stem or epithelial cells. Transcriptional profiling of sensory neurons in the geniculate ganglion, whose fibers innervate fungiform taste buds, indicate that ACE2 and TMPRSS2 are not expressed ([Figure 4](#fig4){ref-type="fig"}; [@bib47]; [@bib190]). Similarly, the vagal sensory neurons that innervate taste buds in the larynx do not express ACE2 or TMPRSS2 ([@bib129]). Obtaining more extensive data regarding SARS-CoV-2-relevant gene expression in taste epithelial populations (which have been woefully undersampled compared to similar populations in the olfactory system) will provide a better basis from which to propose mechanistic hypotheses.

In addition to taste and smell perturbations, subsets of COVID-19 patients experience a disruption of chemesthesis. Chemesthesic stimuli are detected by a variety of epithelial sensors and relayed to the brainstem via trigeminal ganglion sensory neurons, distinct branches of which innervate the nasal respiratory RE and the non-taste epithelium of the tongue, among other targets ([@bib55]; [@bib169]). These trigeminal somatosensory afferents are enriched for TRP channel receptors that detect chemical irritants ([@bib136]). In the nasal cavity, several irritants are detected by solitary chemosensory cells (SCCs), which express many of the molecules required for bitter taste detection and signal transduction that characterize type II TRCs and are innervated by trigeminal fibers ([@bib51]; [@bib62]; [@bib159]). SCCs are capable of driving systemic physiological responses to aversive substances (like reduced respiration) and can recruit a local neurogenic inflammatory response ([@bib139]; [@bib159]). As with the type I TRCs, it is not yet clear from sequencing data whether SCCs express SARS-CoV-2 cell entry genes. Thus how SARS-CoV-2 influences chemesthesis remains uncertain, although these effects are unlikely to be mediated by trigeminal neurons, which do not express ACE2 or TRMPSS2 ([@bib116], [@bib117]).

Conclusions and Outlook {#sec1.6}
-----------------------

Research into possible mechanisms underlying changes in chemical perception due to COVID-19 has only just begun, and much remains to be learned about the pathophysiology of SARS-CoV-2. That said, current evidence favors a model in which SARS-CoV-2 cell entry genes in the olfactory, gustatory, and chemesthetic systems are not expressed in primary or secondary neurons, but rather are expressed in epithelial, support, and stem cells responsible for maintaining perception. This model suggests that neural function is altered indirectly due to sequelae of SARS-CoV-2 infection of peripheral support cells, including (but not limited to) local inflammation and changes in OSN gene expression and ciliary structure. Observed disease-associated changes in OB MRI intensity suggest that in a subset of patients, there is central involvement as well; given the transient nature of these changes, it is likely that they reflect either local inflammatory processes (that are, for example, a consequence of vascular infection) or more speculatively are a consequence of inflammatory cytokines diffusing from the dorsal epithelium across the perforations in the cribriform plate. Although less likely given current evidence, it also remains possible that SARS-CoV-2 directly infects OSNs or bulb neurons.

The notion that chemical sensory deficits in COVID-19 result from infection of support cells highlights an important lacuna in our understanding: while an enormous amount of effort has been devoted to understanding the molecular mechanisms underlying chemosensation---and the neural pathways that convey information about chemical cues to the brain---we still know little about the non-neuronal cells and structures that support sensory transduction. In this sense, SARS-CoV-2 provides an important opportunity to gain insight into how the complex peripheral tissues that support taste, smell, and chemesthesis enable meaningful interactions with the world.

Much of our current understanding of pathophysiological mechanisms has been inferred from patterns of ACE2 and TMPRSS2 expression. However, these inferences are constrained by our current understanding of the virus and by the predicted relationship between ACE2 mRNA and protein. Although the evidence that ACE2 is obligate for SARS-CoV-2 entry is strong, it has been suggested that other molecules such as BSG, neuropilin-1, or PIKfyve may participate in SARS-CoV-2 entry ([@bib23]; [@bib26]; [@bib84]; [@bib120]; [@bib177]). Furthermore, it has recently been reported that low-level expression of ACE2 may be sufficient to support SARS-CoV-2 infection ([@bib91]), suggesting that SARS-CoV-2 may infect apparently ACE2-negative cell types. It is also important to note that many of the conclusions drawn about cell entry gene expression (in, for instance, the olfactory bulb) are based largely upon mouse data. Although the mouse and human ACE2 and TMPRSS2 expression data align nearly perfectly in the olfactory epithelium ([@bib20]), there may be clinically relevant divergences between species in the olfactory bulb and brain ([@bib72]; [@bib105]). Finally, it is important to note that the ACE2 gene is regulated by inflammation in human cells, and other SARS-CoV-2 entry genes may be similarly modulated by primary infection and inflammation ([@bib3]; [@bib196]). This observation raises the possibility that a broader spectrum of cells expresses ACE2 during SARS-CoV-2 infection than is currently appreciated.

Given the emerging central role of support cells in COVID pathophysiology, a key open question is how primary infection of non-neural cells alters chemical perception. Defining the pathophysiological mechanisms underlying anosmia and other SARS-CoV-2-associated disturbances in chemical sensation will require moving past inference based upon gene or protein expression and toward interrogative experiments aimed at falsifying hypotheses about the mechanistic links between, e.g., viral infection, sustentacular cell dysfunction, and altered OSN signaling. For example, the close anatomical apposition of sustentacular cell processes and OSN cilia suggest a direct role in the former in supporting the latter, but the nature of this support and how it might be abrogated after SARS-CoV-2 infection remains enigmatic.

Addressing mechanistic hypotheses will be facilitated by further experiments in mouse models in which human ACE2 is expressed under the control of the mouse ACE2 promoter ([@bib154]) and by more extensive use of non-mouse model organisms, such as hamsters, ferrets, cats, and monkeys, all of which are susceptible to infection by SARS-CoV-2 ([@bib21]; [@bib113]; [@bib147]; [@bib150]). Similarly, the development and use of benign viruses pseudotyped with the SARS-CoV-2 spike protein can be used to identify targeted cell types without the burden of a BSL-3 containment system. Developing tools to characterize the pattern of infection of SARS-CoV-2 in the olfactory system should be complemented by physiological studies in the OE, OB, and cortex---and parallel behavioral work---exploring how the function of the olfactory system evolves after SARS-CoV-2 infection. Importantly, the olfactory epithelium and tongue can be sampled in live human subjects without dissection, which holds the promise for their use as models for characterizing SARS-CoV-2 interactions with the human nervous system. All of this SARS-CoV-2-specific work will be usefully complemented by additional work exploring the physiological function of support cells in the nose and tongue.

Finally, ongoing basic science efforts will benefit from more and better clinical data ([@bib180]). Given the diversity of symptoms reported by patients, it remains unclear whether COVID-19 attacks chemosensation through one or many pathophysiological mechanisms, or whether specific smell or taste qualities are particularly affected. Similarly, we lack an understanding of how smell, taste, and chemesthesis evolve over the long term in the subset of patients that do not exhibit a quick recovery. Revealing the mechanisms through which SARS-CoV-2 influences chemical sensing will have important implications for our understanding of how viruses can functionally alter sensory systems in specific, and neural circuits more generally.
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